Skip to main content
Equibles
IMMX logo

IMMX · Immix Biopharma, Inc. · Metrics

Track IMMX — free

Use IMMX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IMMX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.05 -0.01 (-0.12%) At close · Oct 27
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 7, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which may materially and adversely affect its business, financial condition and operations.”
View the 10-Q filed Aug 7, 2026
Market Cap
$576.61M
Shares
71.54M
Volume · Oct 27 1.15M Avg daily vol (3M) 1.54M

IMMX metrics

58 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.05
Market cap
$576.61M

Price action

20 metrics
Price change (1W)
-1.9%
Price change (30D)
-29.7%
Price change (3M)
-7.2%
Price change (6M)
-15.4%
Price change (YTD)
+54.1%
Price change (1Y)
+123.3%
Trailing year
Price change (5Y)
—
52-week high
$14.47
52-week low
$3.03
Change from 52-week high
-44.3%
Change from 52-week low
+166.0%
Annualized volatility
85.0%
Annualized volatility (3M)
72.7%
Beta
1.6
RSI (14D)
32.7
Price vs SMA 50
-29.1%
Price vs SMA 200
-14.4%
Avg volume (3M)
1.56M
Relative volume
0.7
Average dollar volume
$17.16M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
71.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.5
reciprocal yield 39.3%
FCF yield
-6.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-6.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$41.82M
Net income (TTM)
−$39.88M
Trailing 12 months
Diluted EPS (TTM)
$-0.88
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.77

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+112.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-17.4%
Return on assets
-16.7%
Debt / equity
0.0
Current ratio
25.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$39.09M
Quick ratio
25.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$232.11M
Latest balance sheet
Cash & equivalents
$225.49M
Total assets
$239.11M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$38.50M
Capital expenditures (TTM)
$591,111
R&D (TTM)
$21.62M
SG&A (TTM)
—
Stock compensation (TTM)
$2.59M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
109
13F filer change QoQ
+32
Institutional ownership
78.8%
Conviction holders (share of 13F filers)
2.8%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+91.2%
Holder tenure
4.2
Price vs estimated holder cost
+41.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.8%

Short interest

3 metrics
Short interest
15.0%
Latest settlement · 7.5 days to cover
Days to cover
7.5d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1873835 CUSIP 45258H106 13F (30d) 12 filings 12 filers Visit website Investor relations